Search
Etrolizumab
go.drugbank.com/drugs/DB12189Investigational[A244564, A244584] Etrolizumab is a humanized IgG1κ monoclonal antibody directed against the β7 subunit of gastrointestinal α4β7 and αEβ7 integrins that, due to its target specificity, appears as or more
Methionine
go.drugbank.com/drugs/DB00134ApprovedInvestigationalNutraceuticalA sulfur containing essential amino acid that is important in many body functions. It is a chelating agent for heavy metals.
Mixtures: SOLUCION DP-AMINENM-702
go.drugbank.com/drugs/DB05505InvestigationalIt is caused by insufficient oxygen supply to exercising muscles in the lower extremities due to decreased blood flow as a result of sclerosis of peripheral arteries.
Xylazine
go.drugbank.com/drugs/DB11477InvestigationalVet approved[L42680] The intentional and unintentional use of xylazine is a cause for concern due to its side effects.
Apalutamide
go.drugbank.com/drugs/DB11901ApprovedInvestigationalHigher prostate-specific antigen (PSA) and shorter PSA doubling time (PSA DT) are associated with a higher risk for metastases and death [A31846].
Catridecacog
go.drugbank.com/drugs/DB09310ApprovedCoagulation Factor XIII A-Subunit (Recombinant) is available in the US as the commmercially available product Tretten, and in the EU as NovoThirteen.
Droloxifene
go.drugbank.com/drugs/DB15641ExperimentalDroloxifene has an anti-implantation effect in rats, and the effect appears to be not completely due to its anti-estrogenic activity.[L34184]
Volixibat
go.drugbank.com/drugs/DB13914InvestigationalAccording to Shire, the pharmaceutical manufacturer of Volixibat, it has been granted fast track status by the Food and Drug Administration due to promising initial results and a need for therapeutic treatments
Atorvastatin
go.drugbank.com/drugs/DB01076ApprovedInvestigational[A181397, A181403] Atorvastatin was first synthesized in 1985 by Dr. Bruce Roth and approved by the FDA in 1996.
Barbexaclone
go.drugbank.com/drugs/DB09001ExperimentalThere has been a case of barbexaclone abuse due to the amphetamine like properties of propylhexedrine, although the comparative abuse potential is much lower than amphetamine.